Expert consensus on perioperative treatment decision-making for stage Ⅰ non-small cell lung cancer
10.13406/j.cnki.cyxb.003852
- VernacularTitle:Ⅰ期非小细胞肺癌围术期治疗决策专家共识
- Author:
Yu ZHANG
1
;
Mengxia LI
;
Jianguo SUN
;
Chongqing Precision Lung Oncology Group
Author Information
1. 贵州省人民医院肿瘤科,贵阳 550499
- Keywords:
non-small cell lung cancer;
stage I;
perioperative period;
expert consensus
- From:
Journal of Chongqing Medical University
2025;50(6):703-713
- CountryChina
- Language:Chinese
-
Abstract:
Although stage Ⅰ non-small cell lung cancer(NSCLC)is a type of malignant tumor that can be cured through surgical treatment,its 5-year recurrence rate is still as high as 10%-29%,with a 5-year survival rate of 77%-93.7%.Therefore,better treat-ment strategies are urgently needed to further improve the long-term survival rate of patients with stage I NSCLC.In recent years,ma-jor breakthroughs have been made in targeted therapy and immunotherapy for locally advanced NSCLC in the perioperative period.It was believed in the past that patients with stage I NSCLC had limited benefits from adjuvant chemotherapy,but there are still controver-sies over whether stage I patients can benefit from perioperative targeted therapy and immunotherapy.Therefore,Chongqing Precision Lung Oncology Group discusses the main issues in the treatment of stage I NSCLC in the perioperative period and provides related rec-ommendations,including the selection and optimization of indications for perioperative targeting therapy or immunotherapy,the formu-lation and optimization of regimens and strategies for single therapy or combined therapy,and the optimal time of perioperative target-ing therapy or immunotherapy,so as to provide guidance for clinical practice.
